Drug
MK 6096
MK 6096: highest development phase Phase 2, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| MK-6096 NCT01564459 | Phase 2 | Diabetic Neuropathy, Painful |
Latest
No recent events.
Follow MK 6096 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.